Rally­bio ends de­vel­op­ment in rare dis­or­der; Im­mu­ni­ty­Bio rais­es $75M

Plus, news about KalVista, Kak­en Phar­ma­ceu­ti­cal, Lyell and Tan­go Ther­a­peu­tics:

Rally­bio stops work on RLYB212: The com­pa­ny had been test­ing the drug to see if …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER